A meta-analytic review of the safety and efficacy of semaglutide in type 2 diabetes mellitus and chronic kidney disease patients.

Ann Med Surg (Lond) · 2025 · PMC11981399 · PMID 40212218

Europe PMC DOI

hedged sentences

0.1200

closest p · 2.4× alpha

0.2700

boldest claim

The sentences

a nonsignificant trendp = 0.12not close (p > 0.1)

All-cause mortality With semaglutide treatment, a nonsignificant trend toward reduced all-cause mortality was observed (RR: 0.79; 95% CI: 0.59–1.07; p = 0.12; I 2 = 61%) (Supplemental Digital Content Fig. 2 , available at: http://links.lww.com/MS9/A760 ).

also in 5,406 other papers

did not reach statistical significanceP = 0.27not close (p > 0.1)

This indicates a 20% relative risk reduction in significant kidney adverse events with semaglutide treatment. Nonfatal myocardial infarction The incidence of nonfatal myocardial infarction was lower in the semaglutide group compared to placebo, but this difference did not reach statistical significance (RR: 0.86; 95% CI: 0.66–1.12; P = 0.27; I 2 = 24%) (Fig. 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.